The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Malignant Peripheral Nerve Sheath Tumors
Open accessAbstract
Learning Objectives: Explain the characteristics and treatment of malignant peripheral nerve sheath tumors, both in relation to neurofibromatosis type I and otherwise. Cite the unique challenges in optimal management of malignant peripheral nerve sheath tumors. Appraise the large amount of new data surrounding the potential molecular drivers, possible targets for therapy in this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO classification of tumours of soft tissue and bone
Fletcher, C. D. �. (2013) · Cited by 2,874
van der Graaf, W. T., Blay, J.-Y., Chawla, S. P., Kim, D.-W., Bui-Nguyen, B., Casali, P. G., Schöffski, P., Aglietta, M., Staddon, A. P., Beppu, Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60651-5 · Cited by 2,102
Malignant peripheral nerve sheath tumours in neurofibromatosis 1
Evans, D. G. R., Baser, M. E., McGaughran, J., Sharif, S., Howard, E., & Moran, A. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.5.311 · Cited by 1,282
Pervaiz, N., Colterjohn, N., Farrokhyar, F., Tozer, R., Figueredo, A., & Ghert, M. (2008) · Cancer · doi:10.1002/cncr.23592 · Cited by 987
Neurofibromas in NF1: Schwann Cell Origin and Role of Tumor Environment
Zhu, Y., Ghosh, P., Charnay, P., Burns, D. K., & Parada, L. F. (2002) · Science · doi:10.1126/science.1068452 · Cited by 633
The NF1 tumor suppressor critically regulates TSC2 and mTOR
Johannessen, C. M., Reczek, E. E., James, M. F., Brems, H., Legius, E., & Cichowski, K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503224102 · Cited by 601
tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors
Berghmans, S., Murphey, R. D., Wienholds, E., Neuberg, D., Kutok, J. L., Fletcher, C. D. M., Morris, J. P., Liu, T. X., Schulte-Merker, S., Kanki, J. P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406252102 · Cited by 597
Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas
Maki, R. G., D'Adamo, D. R., Keohan, M. L., Saulle, M., Schuetze, S. M., Undevia, S. D., Livingston, M. B., Cooney, M. M., Hensley, M. L., Mita, M. M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.4495 · Cited by 569
Self-citationMouse Models of Tumor Development in Neurofibromatosis Type 1
Cichowski, K., Shih, T. S., Schmitt, E., Santiago, S., Reilly, K., McLaughlin, M. E., Bronson, R. T., & Jacks, T. (1999) · Science · doi:10.1126/science.286.5447.2172 · Cited by 467
Carli, M., Ferrari, A., Mattke, A., Zanetti, I., Casanova, M., Bisogno, G., Cecchetto, G., Alaggio, R., De Sio, L., Koscielniak, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.4886 · Cited by 371
Zou, C., Smith, K. D., Liu, J., Lahat, G., Myers, S., Wang, W.-L., Zhang, W., McCutcheon, I. E., Slopis, J. M., Lazar, A. J., et al. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181a77e9a · Cited by 313
Gladdy, R. A., Qin, L.-X., Moraco, N., Edgar, M. A., Antonescu, C. R., Alektiar, K. M., Brennan, M. F., & Singer, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1728 · Cited by 289
Ferner, R. E., Golding, J. F., Smith, M., Calonje, E., Jan, W., Sanjayanathan, V., & O’Doherty, M. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm450 · Cited by 286
Kolberg, M., Holand, M., Agesen, T. H., Brekke, H. R., Liestol, K., Hall, K. S., Mertens, F., Picci, P., Smeland, S., & Lothe, R. A. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos287 · Cited by 270
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors
De Raedt, T., Walton, Z., Yecies, J. L., Li, D., Chen, Y., Malone, C. F., Maertens, O., Jeong, S. M., Bronson, R. T., Lebleu, V., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.014 · Cited by 258
Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors
Beert, E., Brems, H., Daniëls, B., De Wever, I., Van Calenbergh, F., Schoenaers, J., Debiec‐Rychter, M., Gevaert, O., De Raedt, T., Van Den Bruel, A., et al. (2011) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20921 · Cited by 255
Phase II Study of Doxorubicin and Bevacizumab for Patients With Metastatic Soft-Tissue Sarcomas
D'Adamo, D. R., Anderson, S. E., Albritton, K., Yamada, J., Riedel, E., Scheu, K., Schwartz, G. K., Chen, H., & Maki, R. G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.139 · Cited by 252
Self-citationRobertson, K. A., Nalepa, G., Yang, F.-C., Bowers, D. C., Ho, C. Y., Hutchins, G. D., Croop, J. M., Vik, T. A., Denne, S. C., Parada, L. F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70414-x · Cited by 234
Rahrmann, E. P., Watson, A. L., Keng, V. W., Choi, K., Moriarity, B. S., Beckmann, D. A., Wolf, N. K., Sarver, A. L., Collins, M. H., Moertel, C. L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2641 · Cited by 169
Porter, D. E., Prasad, V., Foster, L., Dall, G. F., Birch, R., & Grimer, R. J. (2009) · Sarcoma · doi:10.1155/2009/756395 · Cited by 166
LaFemina, J., Qin, L., Moraco, N. H., Antonescu, C. R., Fields, R. C., Crago, A. M., Brennan, M. F., & Singer, S. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2573-2 · Cited by 152
Widemann, B. C., Salzer, W. L., Arceci, R. J., Blaney, S. M., Fox, E., End, D. W., Gillespie, A., Whitcomb, P. O., Palumbo, J. S., Pitney, A. C., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.8638 · Cited by 145
Johansson, G., Mahller, Y. Y., Collins, M. H., Kim, M., Nobukuni, T., Perentesis, J. P., Cripe, T. P., Lane, H. A., Kozma, S. C., Thomas, G., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2335 · Cited by 144
Endo, M., Yamamoto, H., Setsu, N., Kohashi, K., Takahashi, Y., Ishii, T., Iida, K.-I., Matsumoto, Y., Hakozaki, M., Aoki, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1067 · Cited by 144
Katz, D., Lazar, A. J., & Lev, D. C. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001227 · Cited by 139
Ferrari, A., Miceli, R., Rey, A., Oberlin, O., Orbach, D. H., Brennan, B. M. D., Mariani, L., Carli, M., Bisogno, G., Cecchetto, G., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.11.013 · Cited by 138
Albritton, K. H., Rankin, C. J., Coffin, C. M., Ratner, N., Budd, G. T., Schuetze, S. M., Randall, R. L., DeClue, J. E., & Borden, E. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.9518 · Cited by 135
Bottillo, I., Ahlquist, T. C., Brekke, H. R., Danielsen, S. A., van den Berg, E., Mertens, F., Lothe, R. A., & Dallapiccola, B. (2008) · The Journal of Pathology · doi:10.1002/path.2494 · Cited by 133
Subramanian, S., Thayanithy, V., West, R. B., Lee, C., Beck, A. H., Zhu, S., Downs-Kelly, E. P., Montgomery, K. D., Goldblum, J. R., Hogendoorn, P. C. W., et al. (2009) · The Journal of Pathology · doi:10.1002/path.2633 · Cited by 126
Comparative methylome analysis of benign and malignant peripheral nerve sheath tumorsPreprint
Feber, A., Wilson, G. A., Zhang, L., Presneau, N., Idowu, B. D., Down, T. A., Rakyan, V. K., Noon, L. A., Lloyd, A. C., Stupka, E., et al. (2011) · Genome Research · doi:10.1101/gr.109678.110 · Cited by 126
Staser, K. W., Yang, F., & Clapp, D. W. (2011) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132441 · Cited by 125
PTEN dosage is essential for neurofibroma development and malignant transformation
Gregorian, C., Nakashima, J. K., Dry, S., Nghiemphu, P. L., Smith, K. B., Ao, Y., Dang, J. H. T., Lawson, G. W., Mellinghoff, I. K., Mischel, P. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910398106 · Cited by 122
Watson, A. L., Rahrmann, E. P., Moriarity, B. S., Choi, K., Conboy, C. B., Greeley, A. D., Halfond, A. L., Anderson, L. K., Wahl, B. R., Keng, V. W., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0081 · Cited by 111
EGFR–STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors
Wu, J., Patmore, D. M., Jousma, E., Eaves, D. W., Breving, K., Patel, A. V., Schwartz, E. B., Fuchs, J. R., Cripe, T. P., Stemmer-Rachamimov, A. O., et al. (2013) · Oncogene · doi:10.1038/onc.2012.579 · Cited by 106
Lopez, G., Torres, K. E., Liu, J., Hernandez, B., Young, E. D., Belousov, R., Bolshakov, S. V., Lazar, A. J., Slopis, J. M., McCutcheon, I. E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2799 · Cited by 98
Zou, C., Smith, K. D., Zhu, Q.-S., Liu, J., McCutcheon, I. E., Slopis, J. M., Meric‐Bernstam, F., Peng, Z., Bornmann, W. G., Mills, G. B., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1008 · Cited by 93
Kim, A., Dombi, E., Tepas, K., Fox, E., Martin, S. C., Wolters, P. L., Balis, F. M., Jayaprakash, N., Türkbey, B., Muradyan, N., et al. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24281 · Cited by 87
Patel, A. V., Eaves, D. W., Jessen, W. J., Rizvi, T. A., Ecsedy, J., Qian, M. G., Aronow, B. J., Perentesis, J. P., Serra, E., Cripe, T. P., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1072 · Cited by 72
Brekke, H. R., Ribeiro, F. R., Kolberg, M., Ågesen, T. H., Lind, G. E., Eknæs, M., Hall, K. S., Bjerkehagen, B., van den Berg, E., Teixeira, M. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.8989 · Cited by 71
Presneau, N., Eskandarpour, M., Shemais, T. A. H., Henderson, S. R., Halai, D., Tirabosco, R., & Flanagan, A. M. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.518 · Cited by 69
TP53 Mutation Analysis of Malignant Peripheral Nerve Sheath Tumors
Verdijk, R. M., den Bakker, M. A., Dubbink, H. J., Hop, W. C. J., Dinjens, W. N. M., & Kros, J. M. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181c55d55 · Cited by 68
Impaired Pten Expression in Human Malignant Peripheral Nerve Sheath Tumours
Bradtmöller, M., Hartmann, C. J., Zietsch, J., Jäschke, S., Mautner, V., Kurtz, A., Park, S.-J., Baier, M., Harder, A., Reuß, D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047595 · Cited by 67
Storlazzi, C. T., Brekke, H. R., Mandahl, N., Brosjö, O., Smeland, S., Lothe, R. A., & Mertens, F. (2006) · The Journal of Pathology · doi:10.1002/path.1998 · Cited by 55
Ghadimi, M. P., Lopez, G., Torres, K. E., Belousov, R., Young, E. D., Liu, J., Savannah, K. J. B., Hoffman, A., Lusby, K., Lazar, A. J., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0015 · Cited by 49
Klampfer, L., Huang, J., Shirasawa, S., Sasazuki, T., & Augenlicht, L. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0210 · Cited by 32
Thomas, L. E., Mautner, V., Cooper, D. N., & Upadhyaya, M. (2012) · Human Genomics · doi:10.1186/1479-7364-6-18 · Cited by 26
Sleeping Beauty – A mouse model for all cancers?
Howell, V. M. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.11.006 · Cited by 20
Sun, D., Haddad, R., Kraniak, J. M., Horne, S. D., & Tainsky, M. A. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0593 · Cited by 19
Cited by
Chang, L.-S., Oblinger, J. L., Burns, S. S., Huang, J., Anderson, L. W., Hollingshead, M. G., Shen, R., Pan, L., Agarwal, G., Ren, Y., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0809 · Cited by 22
Metadata
- Authors
- Farid, M., Demicco, E. G., Garcia, R., Ahn, L., Merola, P. R., Cioffi, A., & Maki, R. G.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-01-27
- Volume
- 19
- Issue
- 2
- Pages
- 193-201
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2109436606
- Cited by
- 354
- References
- 48
- FWCI
- 9.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.